Poor
Needs Revision
Patient Risk:
Moderate
Summary
Some safety/drug-interaction claims are supported by the provided label excerpts (grapefruit juice; CYP3A4 strong inhibitors context; skeletal muscle/myopathy warning). However, several claims cannot be verified as stated because the provided excerpts do not specifically mention the particular drugs (warfarin, cyclosporine, clarithromycin, itraconazole) or a black box warning. Additionally, the evaluation is limited to the supplied label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Supported indirectly by indication/lipid-lowering excerpts: Sections 1.2 (indicated as adjunct to diet to reduce elevated total-C/LDL-C/apo B/TG and increase HDL-C) and 12.1 mechanism (HMG-CoA reductase inhibitor).
Grapefruit juice can increase the levels of Lipitor in the body, potentially increasing the risk of side effects.
Supported by Section 7.1 Grapefruit Juice: components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive intake (>1.2 L/day). Label excerpt links increased plasma concentrations; statement adds 'potentially increasing the risk of side effects' which is not explicitly stated in the provided grapefruit excerpt.
Unsupported Statements
Lipitor has a black box warning for increased risk of liver damage when taken with certain medications, such as warfarin (Coumadin).
The provided label excerpts do not include any boxed warning or any statement that liver damage risk with concomitant medications (e.g., warfarin) is a black box warning. The provided liver dysfunction excerpt discusses liver enzyme abnormalities but does not specify a boxed warning or warfarin.
Combining Lipitor with cyclosporine (Neoral) may increase the risk of muscle damage (rhabdomyolysis).
The provided excerpts include a general skeletal muscle/rhabdomyolysis warning (Section 5.1) and general CYP3A4 strong inhibitor interaction concept (Section 7.1), but they do not specifically mention cyclosporine or cyclosporine-associated rhabdomyolysis.
Clarithromycin (Biaxin) may increase the risk of muscle damage when combined with Lipitor.
The provided excerpts do not specifically mention clarithromycin.
Itraconazole (Sporanox) may increase the risk of muscle damage when combined with Lipitor.
The provided excerpts do not specifically mention itraconazole.
Combining Lipitor with cyclosporine (Neoral) may increase the risk of muscle damage (rhabdomyolysis).
Not directly supported: Section 5.1 notes rare cases of rhabdomyolysis with LIPITOR and other drugs in this class, but without identifying cyclosporine as a specific interacting agent in the provided text.
Contradictions
Low
AI Statement
Lipitor has a black box warning for increased risk of liver damage when taken with certain medications, such as warfarin (Coumadin).
Label Reference
No boxed warning content or warfarin-specific boxed warning is present in the provided excerpts; treating 'black box warning for liver damage with warfarin' as contradictory to the provided excerpts’ content would be speculative. Marked as unsupported rather than a direct contradiction.
Important Omissions
For the interaction statements, the label excerpt provided supports the general concept that strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations, but it does not provide the specific drug examples (warfarin, cyclosporine, clarithromycin, itraconazole).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several drug-interaction statements name specific concomitant drugs as increasing rhabdomyolysis risk, but the provided label excerpts do not substantiate those specific pairings or the 'black box warning' assertion. Grapefruit juice interaction is supported for increased plasma concentrations, though the added 'side effects risk' is not explicitly stated in the excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Over-specific interaction claims (warfarin, cyclosporine, clarithromycin, itraconazole) and an asserted boxed warning are not supported by the provided label excerpts.
Suggested Improvement
Restrict interaction statements to what is supported by the excerpted labeling: e.g., cite that strong CYP3A4 inhibitors can increase atorvastatin plasma concentrations and that grapefruit juice can increase atorvastatin concentrations (especially with excessive intake). Remove or rephrase unverified boxed-warning and drug-specific rhabdomyolysis association claims unless supported by the full label.